On the other hand, if anti-cancer therapy is central to cancer therapy in metastatic NSCLC, then we contend that a different design comparing anti-CTLA4 + anti-PD1/L1 with anti-PD1/L1 alone or with anti-PD1/L1 + standard chemotherapy would be more defining and revealing [87]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.